Treatment group	Luminal occlusion	Intima/media ratio
Vehicle (n = 8)	52.8 ± 5.8%	1.02 ± 0.13
low-dose TRAM-34 (n = 7)	21.5 ± 6.2% ($p = 1.65 \times 10^{-5}$)	0.41 ± 0.11 ($p = 4.87 \times 10^{-4}$)
high-dose TRAM-34 (n=6)	22.4 ± 3.4% ($p = 4.72 \times 10^{-5}$)	0.49 ± 0.10 (p = 0.003)
low-dose sirolimus (n = 6)	16.1 ± 3.6% ($p = 2.17 \times 10^{-6}$)	0.31 ± 0.07 ($p = 1.25 \times 10^{-4}$)
high-dose sirolimus (n = 6)	3.9 ± 1.2% ($p = 4.89 \times 10^{-9}$)	0.05 ± 0.01 ($p = 8.64 \times 10^{-7}$)
low-dose TRAM-34 plus low-dose sirolimus (n = 5)	16.7 ± 3.7% ($p = 7.66 \times 10^{-6}$)	0.27 ± 0.09 ($p = 1.24 \times 10^{-4}$)
PAP-1 (n = 6)	38.0 ± 5.8% (p = 0.03)	0.95 ± 0.22
isograft (n = 4)	0.6 ± 0.2% ($p = 2.08 \times 10^{-8}$)	0.03 ± 0.00 ($p = 5.3 \times 10^{-6}$)

Supporting Table 1.
Percentage of luminal occlusion and intima/media ratios evaluated at three different levels of each harvested graft in the different treatment groups.

Treatment group	Adventitia [μm]	Adventitia MNCs	Media [μm]	Media MNCs	Intima [μm]	Intima MNCs
Vehicle (n = 8)	41248 ± 9242	2865 ± 480	23462 ± 1992 p = NS	1439 ± 375	24090 ± 4185	1195 ± 173
low-dose TRAM-34 (n = 7)	22856 ± 4686 p = 0.01	2336 ± 511 p = NS	22145 ± 12078 p = NS	932 ± 240 p = 0.09	8832 ± 2488 $p = 3.6 \times 10^{-4}$	778 ± 317 p = NS
high-dose TRAM-34 (n=6)	22369 ± 4474 p = 0.01	2063 ± 665 p = NS	22060 ± 1830 p = NS	551 ± 169 p = 0.006	10473 ± 2359 p = 0.002	442 ± 92 p = 0.002
low-dose sirolimus (n = 6)	22101 ± 3897 p = 0.01	1610 ± 402 p = NS	29347 ± 3684 p = NS	613 ± 150 p = 0.01	8718 ± 2180 $p = 5.40 \times 10^{-4}$	799 ± 154 p = 0.09
high-dose sirolimus (n = 6)	4612 ± 1883 $p = 2.1 \times 10^{-4}$	417 ± 147 $p = 3.89 \times 10^{-4}$	19423 ± 659 p = NS	221 ± 74 $p = 2.88 \times 10^{-4}$	1051 ± 243 $p = 1.32 \times 10^{-6}$	233 ± 89 $p = 1.16 \times 10^{-4}$
low-dose TRAM-34 plus low-dose sirolimus (n = 5)	12045 ± 1887 $p = 4.55 \times 10^{-4}$	1069 ± 516 p = 0.01	18970 ± 834 p = NS	396 ± 149 p = 0.003	5255 ± 1930 $p = 8.4 \times 10^{-5}$	224 ± 74 $p = 2.08 \times 10^{-4}$
PAP-1 (n = 6)	24691 ± 5267 p = 0.03	3039 ± 493 p = NS	18697 ± 2464 p = NS	670 ± 203 p = 0.017	17261 ± 3712 p = 0.10	528 ± 117 p = 0.005
isograft (n = 4)	17442 ± 2877 p = 0.006	229 ± 51 $p = 6.96 \times 10^{-4}$	14893 ± 604 p = 0.0058	119 ± 21 $p = 4.89 \times 10^{-4}$	410 ± 45 $p = 7.6 \times 10^{-6}$	1.75 ± 0.25 $p = 3.26 \times 10^{-5}$

Supporting Table 2.
Averaged adventitia, media and intima areas measured at three levels in each harvested graft are given in μm^2. Total mononuclear cell numbers were determined in the same sections.

Rat Orthotopic Allograft Aorta Transplant (120-day Vehicle Treatment)



Allograft H&E



Allograft α-SMA



Allograft ED1



Allograft KCa3.1

Rat Orthotopic Isograft Aorta Transplant (120-day Vehicle Treatment)



Isograft KCa3.1



Isograft KCa3.1

Supporting Figure 1. KCa3.1 expression in rat vasculopathy. A, B, C, D, Serial sections stained with H&E or antibodies against α-SMA, the macrophage marker ED1 (= CD68) and KCa3.1. Sections A, B, C and D are sequential and each section is 5 µm from the previous section. **E**, KCa3.1 expression on the vascular endothelium of an isograft. **F,** Close-up of the boxed area in E.



Supporting Figure 2. Specificity of Kv1.3 antibody (Sigma P9170) in mouse and rat spleen.
A, B, Sequential rat spleen sections stained with the polyclonal anti-Kv1.3 antibody (P9170; 1:750) or secondary antibody only. **C, D, E,** Kv1.3 staining in mouse spleen. C and D are wild-type mouse spleen sections stained with anti-Kv1.3 (1:750) or secondary antibody only. E shows a Kv1.3 knock-out mouse spleen section stained for Kv1.3 (1:750). In all sections secondary antibody binding is visualized by DAB. Sections are counterstained with hematoxylin.